News Safety restrictions spell the end for Servier osteoporosis d... Sales of Protelos hit by safety restrictions.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Pfizer's fast-tracked leukaemia candidate could rival CAR-Ts Antibody-drug conjugate with FDA gets six-month review.
News Amgen/UCB reveal new osteoporosis drug data But romosozumab missed secondary endpoint of non-vertebral fractures
Articles Stop being control freaks: pharma’s challenge in involving p... Lode Dewulf, chief patient affairs officer at UCB, tells Paul Tunnah how patient-centricity is evolving, and describes how pharma still needs to adapt.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
